Clinical trials: Treatment Resistant Depressive Disorder
Major Depression Disorder
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD).
- Trial name
- PROMET_TMS (NCT07039370)
- Testing
- TMS
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression Severe
Brain Stimulation for Severe Depression
Chronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull.
- Trial name
- NCT05393622
- Testing
- INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Inner Cosmos Inc
Treatment Resistant Depression
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant…
- Trial name
- NCT05660642
- Testing
- BPL-003
- Where
- 3 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- Beckley Psytech Limited
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- aTBS (NCT03068715)
- Testing
- Active TBS-DLPFC, Open label TBS-DLPFC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Schizophrenia, Diabetes
Medication Reviews in Severe Mental Illness
This study aims to investigate the potential beneficial effects of a medication review by a clinical pharmacologist on patients with coexisting severe mental illness and diabetes.
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Severe Mental Disorder
- Trial name
- NCT05243160
- Testing
- medication review
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Major Depressive Disorder
Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
The purpose of this study is to identify evidence-based guidelines for treating major depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients.
- Trial name
- NCT01699490
- Testing
- Fluoxetine + Valsartan
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Cheng-Kung University Hospital
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai